Bexarotene reduces blood-brain barrier permeability in cerebral ischemia- reperfusion injured rats

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Xu, Lu ^a   Cao, Fang ^a   Xu, Feng ^a   He, Baicheng ^a   Dong, Zhi ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; BEXAROTENE; CLAUDIN 5; EVANS BLUE; GADODIAMIDE; GELATINASE B; MESSENGER RNA; OCCLUDIN; CLDN5 PROTEIN, RAT; MMP9 PROTEIN, RAT; NEUROPROTECTIVE AGENT; OCLN PROTEIN, RAT; TETRALIN DERIVATIVE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD BRAIN BARRIER DYSFUNCTION; BRAIN ISCHEMIA; BRAIN WATER; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRY WET WEIGHT METHOD; ENZYME ACTIVITY; ENZYME ANALYSIS; GELATIN ZYMOGRAPHY; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; MALE; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY; ANIMAL; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM;

RATTUS;

ANIMALS; APOLIPOPROTEINS E; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; CLAUDIN-5; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; MALE; MATRIX METALLOPROTEINASE 9; NEUROPROTECTIVE AGENTS; OCCLUDIN; RATS; TETRAHYDRONAPHTHALENES;

EID: 84927539300     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122744     Document Type: Article

References (30)

1. Yamashita T, Abe K (2011) Therapeutic approaches to vascular protection in ischemic stroke. Acta Med Okayama 65: 219-223. PMID: 21860527.
2. Adibhatla RM, Hatcher JF (2008) Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: Therapeutic strategies. CNS Neurol Disord Drug Targets 7: 243-253. PMID: 18673209.
3. Vonderheid EC (2003) Treatment planning in cutaneous T-cell lymphoma. Dermatol Ther 16: 276- 282. PMID: 14686969.
4. Fu J, Wang W, Liu YH, Lu H, Luo Y (2011) In vitro anti-angiogenic properties of LGD1069, a selective retinoid X-receptor agonist through down-regulating Runx2 expression on Human endothelial cells. BMC Cancer 11: 227. doi:10.1186/1471-2407-11-227 PMID: 21649908.
5. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn A. E., et al. (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335: 1503-1506. doi:10.1126/science.1217697 PMID: 22323736.
6. Longa EZ, Weinstein PR, Carlson S, Cummins R (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20: 84-91. PMID: 2643202.
7. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z., et al. (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485: 512-516. doi:10.1038/nature11087 PMID: 22622580.
8. Zheng M, Wei J, Tang Y, Yang C, Wei Y, Yin X. et al. (2014) ApoE-deficient promotes blood-brain barrier disruption in experimental autoimmune encephalomyelitis via alteration of MMP-9. J Mol Neurosci 54: 282-290. doi:10.1007/s12031-014-0291-xPMID: 24788224.
9. Luissint AC, Artus C, Glacial F, Ganeshamoorthy K, Couraud PO (2012) Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS 9: 23. doi:10.1186/2045-8118-9-23PMID: 23140302.
10. Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz M. A. et al. (2001) Effects of matrix metalloproteinase- 9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21: 7724-7732. PMID: 11567062.
11. Chen F, Ohashi N, Li W, Eckman C, Nguyen JH (2009) Disruptions of occludin and claudin-5 in brain endothelial cells in vitro and in brains of mice with acute liver failure. Hepatology 50: 1914-1923. doi:10.1002/hep.23203PMID: 19821483.
12. Xin H, Liang W, Mang J, Lin L, Guo N, Zhang F. et al. (2012) Relationship of gelatinases-tight junction proteins and blood-brain barrier permeability in the early stage of cerebral ischemia and reperfusion. Neural Regen Res 7: 2405-2412. doi:10.3969/j.issn.1673-5374.2012.31.001 PMID: 25337090.
13. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR (1997) Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 238: 53-56. PMID: 9464653.
14. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo G. J. et al. (1999) Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 19: 624-633. PMID: 10366192.
15. Shimbo D, Abumiya T, Shichinohe H, Nakayama N, Kazumata K, Houkin K. et al. (2014) Post-ischemic intra-arterial infusion of liposome-encapsulated hemoglobin can reduce ischemia reperfusion injury. Brain Res 1554: 59-66. doi:10.1016/j.brainres.2014.01.038 PMID: 24486612.
16. Liu Y, Wang D, Wang H, Qu Y, Xiao X, Zhu Y. et al. (2014) The protective effect of HET0016 on brain edema and blood-brain barrier dysfunction after cerebral ischemia/reperfusion. Brain Res 1544: 45- 53. doi:10.1016/j.brainres.2013.11.031 PMID: 24316243.
17. Wu Y, Wang L, Dai C, Ma G, Zhang Y, Zhang X. et al. (2014) Neuroprotection by platelet-activating factor acetylhydrolase in a mouse model of transient cerebral ischemia. Neurosci Lett 558: 26-30. doi:10.1016/j.neulet.2013.09.005 PMID: 24189491.
18. Akamatsu Y, Saito A, Fujimura M, Shimizu H, Mekawy M, Hasumi K. et al. (2011) Stachybotrys microspora triprenyl phenol-7, a novel fibrinolytic agent, suppresses superoxide production, matrix metalloproteinase- 9 expression, and thereby attenuates ischemia/reperfusion injury in rat brain. Neurosci Lett 503: 110-114. doi:10.1016/j.neulet.2011.08.018 PMID: 21871536.
19. Lynch JR, Morgan D, Mance J, Matthew WD, Laskowitz DT (2001) Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. J Neuroimmunol 114: 107-113. PMID: 11240021.
20. Lomnitski L, Chapman S, Hochman A, Kohen R, Shohami E, Chen Y. et al. (1999) Antioxidant mechanisms in apolipoprotein E deficient mice prior to and following closed head injury. Biochim Biophys Acta 1453: 359-368. PMID: 10101254.
21. Zhou S, Wu H, Zeng C, Xiong X, Tang S, Tang Z. et al. (2013) Apolipoprotein E protects astrocytes from hypoxia and glutamate-induced apoptosis. FEBS Lett 587: 254-258doi:10.1016/j.febslet.2012.12.003 PMID: 23238080.
22. Nishitsuji K, Hosono T, Nakamura T, Bu G, Michikawa M (2011) Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model. J Biol Chem 286: 17536-17542. doi:10.1074/jbc.M111.225532 PMID: 21471207.
23. Methia N, Andre P, Hafezi-Moghadam A, Economopoulos M, Thomas KL, Wagner D. D. et al. (2001) ApoE deficiency compromises the blood brain barrier especially after injury. Mol Med 7: 810-815. PMID: 11844869.
24. Lynch JR, Pineda JA, Morgan D, Zhang L, Warner DS, Benveniste H., et al. (2002) Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema. Ann Neurol 51: 113-117. PMID: 11782990.
25. Fullerton SM, Shirman GA, Strittmatter WJ, Matthew WD (2001) Impairment of the blood-nerve and blood-brain barriers in apolipoprotein e knockout mice. Exp Neurol 169: 13-22. PMID: 11312553.
26. Horsburgh K, McCulloch J, Nilsen M, McCracken E, Large C, Roses A. D., et al. (2000) Intraventricular infusion of apolipoprotein E ameliorates acute neuronal damage after global cerebral ischemia in mice. J Cereb Blood Flow Metab 20: 458-462. PMID: 10724109.
27. Ulrich JD, Burchett JM, Restivo JL, Schuler DR, Verghese PB, et al. (2013) In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol Neurodegener 8: 13. doi:10.1186/1750-1326-8-13 PMID: 23601557.
28. McFarland K, Spalding TA, Hubbard D, Ma JN, Olsson R, Mahan T. E. et al. (2013) Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease. ACS Chem Neurosci 4: 1430-1438. doi:10.1021/cn400100fPMID:24117438.
29. Lerner V, Miodownik C, Gibel A, Sirota P, Bush I, Elliot H., et al. (2013) The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: A 6-week, randomized, double-blind, placebo- controlled multicenter trial. J Clin Psychiatry 74: 1224-1232. doi:10.4088/JCP.12m08160 PMID: 24434091.
30. Bomben V, Holth J, Reed J, Cramer P, Landreth G, Noebels J. et al. (2014) Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy. Neurobiol Aging 35: 2091-2095. doi:10.1016/j.neurobiolaging.2014.03.029 PMID: 24767949.